PALVELLA THERAPEUTICS, INC.
PVLADrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
PVLA Earnings Report
EPS Est: $-1.16 | FQ end 2026-06 | Call: 2026-08-04 15:00:00
How PVLA's past catalysts played out
QTORIN 3.9% Rapamycin Anhydrous Gel
Microcystic Lymphatic Malformation
PTX-022
Pachyonychia Congenita
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
QTORIN 3.9% Rapamycin Anhydrous Gel | Phase 3 | Microcystic Lymphatic Malformation | - | - |
PTX-022 | Phase 3 | Pachyonychia Congenita | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in PALVELLA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in PALVELLA THERAPEUTICS, INC.'s (PVLA) pipeline across Phase 3. Its lead program is QTORIN 3.9% Rapamycin Anhydrous Gel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PALVELLA THERAPEUTICS, INC.'s next FDA catalyst?→
PALVELLA THERAPEUTICS, INC.'s (PVLA) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PVLA biotech catalysts?→
Add PVLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PALVELLA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.